Research programme: antibody radionucleotide conjugates - AREVA Med/Nordic NanovectorAlternative Names: Anti-CD37 212Pb-ARC - AREVA Med/Nordic Nanovector; Lead-212 conjugated anti-CD37 antibody - AREVA Med/Nordic Nanovector
Latest Information Update: 04 Jul 2016
At a glance
- Originator AREVA Med; Nordic Nanovector
- Developer AREVA Med
- Class Antibodies; Antineoplastics; Immunoconjugates; Radiopharmaceuticals
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Leukaemia